创50ETF(159681)量价齐升，乐普医疗近20%涨停，券商看好创新药+器械双主线

Group 1 - The core viewpoint of the news highlights the significant rise in the 创50ETF and its constituent stocks, driven by a licensing agreement between Bristol-Myers Squibb and BioNTech for a new cancer drug, BNT327, with milestone payments potentially reaching $11.1 billion [1] - The 创50ETF increased by 1.26%, while the associated index, 创业板50, rose by 1.44%, indicating a positive market sentiment [1] - Notable stock performances included 乐普医疗, which surged by 19.98%, and 新易盛, which rose by 7.76%, reflecting the overall bullish trend in the biopharmaceutical sector [1] Group 2 - 中邮证券 reported that the innovative drug sector is experiencing a surge, with 53 new drugs approved in China from early 2025 to the end of May, including 30 domestic innovative drugs, covering areas such as oncology and autoimmune diseases [1] - The CXO sector also saw a 4% increase this week, benefiting from the innovative drug market and a recovery in overseas financing, with leading companies like 药明康德 and 康龙化成 showing optimistic performance guidance for 2025 [1] - There may be performance differentiation among smaller companies due to varying proportions of overseas revenue, indicating potential risks in the sector [1]